Clinical Trials Feature Articles

31. ICON Insight: Leveraging Patient Registries To Assess Safety And Product Performance In The Post-Approval Arena
    5/6/2008

    The drug development path today is more challenging and expensive than ever. The cost of bringing a new drug to market is estimated at somewhere between $500 million and $1 billion. With this intense development investment, it's critical, then, for the drug to remain on the market after approval — an outcome that is not nearly as certain today as it was in decades past. Submitted by ICON Clinical Research

32. Gentle, Cell-Sensitive Pumping
    3/19/2008
    Comparison of different peristaltic pump systems for use in animal cell cultures
33. ICON Insight: Enhancing Patient Recruitment: How Sites, Sponsors, And CROs Can Interact More Effectively
    3/5/2008
    Patient recruitment is one of the most critical challenges to overcome in clinical trials. It accounts for over 27% of the cost of drug development today. Yet more than 80% of clinical trials will miss their enrollment deadlines. In the U.S., on average, most studies are delayed by at least six months. These delays can cost pharmaceutical companies millions of dollars in sales. Submitted by ICON
34. Article: Adaptive Trial Designs In Late Phase Drug Development
    3/4/2008
    Article: Adaptive Trial Designs In Late Phase Drug Development
35. Adaptive Trial Designs In Late Phase Drug Development
    3/4/2008
    Before regulatory agencies approve a new drug, they require substantial evidence of the effectiveness and safety through clinical trials. Most clinical trials are static in nature and designated as Phase I, II, or III based on the type of questions that the trial is seeking to answer. With increasing pressure to bring drugs to market faster and more cheaply, the current development paradigm is being challenged. Submitted by ICON
36. Advanced Science And The Art Of Letting Go: Considerations In Transferring Cytometric Assays From The Bench To A Central Laboratory
    3/4/2008
    A pre-clinical scientist at a biotechnology company and the director of a cellular immunology laboratory at a global central laboratory describe the science and the reassurance required with a technology transfer associated with a later phase clinical trial. Submitted by ICON
37. Article: Clinical Trials In Diabetes: Challenges In Patient Recruitment
    3/4/2008
    Article: Clinical Trials In Diabetes: Challenges In Patient Recruitment
38. Clinical Trials In Diabetes: Challenges In Patient Recruitment
    3/4/2008
    Because of the large number of patients and trial sites needed for diabetes trials, they can be complicated to set up and run. In this competitive environment, there are several challenges that must be overcome in order to conduct a successful trial on time and on budget. Submitted by ICON
39. Article: Patient Registries: A New Gold Standard For Real World Research
    3/4/2008
    Article: Patient Registries: A New Gold Standard For Real World Research
40. Patient Registries: A New Gold Standard For Real World Research
    3/4/2008
    Physicians in community-based practice rarely have the time, nor the inclination, to participate in formal, randomized controlled clinical research. While few would question the importance of statistically valid clinical trials focused on establishing the safety and efficacy of new pharmaceuticals and medical devices, most busy practitioners recognize that formal clinical research can't be approached casually. Submitted by ICON